Adjuvant rituximab, a potential treatment for the young patient with Graves hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial
Abstract
This protocol paper describes an innovative phase II trial to study the effect of a single low dose of adjuvant rituximab (a chimeric anti-B-cell monoclonal antibody targeting the surface molecule CD20) compared to classical carbimazole therapy in adolescents and young adults with Graves disease. Carbimazole treatment will be stopped after 12 months and the primary endpoint remission of Graves disease will be analysed at 24...
Paper Details
Title
Adjuvant rituximab, a potential treatment for the young patient with Graves hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial
Published Date
Sep 12, 2019
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History